&nbsp;

May 2025

Regimen

IBRU+RITU

Cancer Type:

Hematologic

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - In Combination with Rituximab for Previously Treated Waldenstrӧms Macroglobulinemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia

, Collapse Show fewer tags

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2025

Drug

asciminib

Other Name(s): Scemblix™

Quick Link(s):

Sep 2025

Regimen

AZCTIVOS

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Curative

Funding:

New Drug Funding Program

Azacitidine in combination with Ivosidenib (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

Ivosidenib in combination with Azacitidine (Outpatient) - Previously Untreated Acute Myeloid Leukemia

, Collapse Show fewer tags

Drugs Used:

ivosidenib,

azaCITIDine

... Show more tags

Quick Link(s):

Regimen Monograph

Sep 2025

Drug

larotrectinib

Other Name(s): Vitrakvi®

Quick Link(s):

Sep 2025

Drug

belzutifan

Other Name(s): Welireg®

Quick Link(s):

Updated

Sep 2025

Drug

niraparib / abiraterone

Other Name(s): Akeega™

Quick Link(s):

Updated

Sep 2025

Drug

luspatercept

Other Name(s): Reblozyl®

Quick Link(s):

Updated

Sep 2025

Drug

iBRUtinib

Other Name(s): Imbruvica®

Quick Link(s):

Updated

Sep 2025

Drug

lapatinib

Other Name(s): Tykerb®

Quick Link(s):

Updated

Sep 2025

Drug

ivosidenib

Other Name(s): Tibsovo®

Quick Link(s):

Updated

Oct 2025

Drug

palbociclib

Other Name(s): Ibrance™

Quick Link(s):